Intervention
sitagliptin
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 44 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
44 shownEfficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.NCT02849080 · 2016-09-20
COMPLETEDEfficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 DiabetesNCT02607865 · 2016-02-15
COMPLETEDA Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 DiabetesNCT02254291 · 2014-10-02
COMPLETEDInfluence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass SurgeryNCT02336659 · 2014-04-01
COMPLETEDA Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in SwedenNCT02077946 · 2014-02-10
COMPLETEDEfficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and MetforminNCT01907854 · 2013-12-02
COMPLETEDEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 DiabetesNCT01930188 · 2013-12-02
COMPLETEDThe Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 DiabetesNCT02008682 · 2013-12-01
COMPLETEDEffects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin TherapyNCT01859793 · 2013-06-01
COMPLETEDCorrelation Between Plasma- and Endothelial DPP-4 ActivityNCT02192853 · 2013-05-01
COMPLETEDA Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesNCT01455870 · 2013-05-01
COMPLETEDA Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesNCT01455909 · 2013-02-01
WITHDRAWNTreatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and MetforminNCT01519674 · 2012-06-01
COMPLETEDSitagliptin in Type I Diabetic PatientsNCT01741103 · 2011-06-01
WITHDRAWNComparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)NCT01296412 · 2011-03-11
COMPLETEDSitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 DiabetesNCT01260246 · 2010-12-01
TERMINATEDChanges in Bone Turnover With Increased Incretin Hormone ExposureNCT01374568 · 2010-07-01
TERMINATEDA Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.NCT01098539 · 2010-05-01
COMPLETEDSitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin TreatmentNCT01100125 · 2010-04-01
COMPLETEDEffect of Sitagliptin on Postprandial Lipoprotein MetabolismNCT00939939 · 2010-03-01
TERMINATEDSitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2DNCT02607410 · 2010-01-01
COMPLETEDComparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With InsulinNCT01046110 · 2010-01-01
COMPLETEDProtective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)NCT01159847 · 2010-01-01
COMPLETEDSafety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of MetforminNCT00998686 · 2009-11-01
TERMINATEDStudy to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal ImpairmentNCT00958269 · 2009-08-01
TERMINATEDEffect of Sitagliptin on Graft Function Following Islet TransplantationNCT00853944 · 2009-07-01
TERMINATEDA Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)NCT00888238 · 2009-05-12
COMPLETEDEfficacy and Safety of Albiglutide in Treatment of Type 2 DiabetesNCT00838903 · 2009-02-01
COMPLETEDThe Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)NCT00832624 · 2008-11-26
TERMINATEDSafety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)NCT00676338 · 2008-11-01
COMPLETEDEffect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 DiabetesNCT00789191 · 2008-11-01
COMPLETEDSitagliptin in Renal Transplant RecipientsNCT00740363 · 2008-09-01
COMPLETEDSafety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)NCT00770081 · 2008-09-01
COMPLETEDBI 10773 add-on to Metformin in Patients With Type 2 DiabetesNCT00749190 · 2008-08-01
COMPLETEDComparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a ThiazolidinedioneNCT00729326 · 2008-08-01
COMPLETEDThe Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes MellitusNCT00700817 · 2008-06-01
COMPLETEDThe Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and InflammationNCT00696982 · 2008-06-01
UNKNOWNA Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)NCT00701090 · 2008-05-01
COMPLETED18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)NCT00666458 · 2008-04-01
COMPLETEDA Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)NCT00637273 · 2008-01-01
COMPLETEDA Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes MellitusNCT00477581 · 2007-05-01
COMPLETEDEffect of Januvia on Beta Cell Function in Patients With Diabetes MellitusNCT00425490 · 2007-01-01
COMPLETEDSitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)NCT00350779 · 2006-06-12
COMPLETEDAn Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)NCT00095056 · 2004-10-01
COMPLETEDCommon conditions
Diabetes Mellitus, Type 217Diabetes13Type 2 Diabetes Mellitus11Type 2 Diabetes4Diabetes Mellitus Type 22Arterial Stiffness1Atherosclerosis1Chronic Renal Insufficiency1Diabetes Mellitus1Diabetes Mellitus Non-insulin-dependent1Diabetes Mellitus, Non-Insulin-Dependent1Diabetes Type I1Glucose Intolerance1Islet Transplantation1Nonalcoholic Steatohepatitis1Renal Impairment1Renal Insufficiency1Severe Obesity1Type 1 Diabetes1Type 2 Diabetes Mellitus, Non Insulin Dependent1
Leading sponsors
Novo Nordisk A/S
11
Merck Sharp & Dohme LLC
6
AstraZeneca
5
GlaxoSmithKline
2
Intarcia Therapeutics
2
Phenomix
2
Assaf-Harofeh Medical Center
1
Boehringer Ingelheim
1
European Foundation for the Study of Diabetes
1
Hvidovre University Hospital
1
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
1
Ludwig-Maximilians - University of Munich
1
Medical College of Wisconsin
1
Novartis
1
Seoul National University Bundang Hospital
1
Trial status mix
COMPLETED34
TERMINATED7
WITHDRAWN2
UNKNOWN1
Phase mix
PHASE323
PHASE413
NA4
PHASE12
PHASE22
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.